Condition: Malignant Neoplasm · Malignant Neoplasm of Brain · Sponsor: Novelwise Pharmaceutical Corporation
NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. This study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors or combination with the standard of care treatment in subjects with newly diagnosed glioblastoma.
This description comes directly from the study's public registry record.
Chia-Chung Hou, Ph.D. · +886 2 26559109 · alison.hou@novelwisepharma.com
Karis Chiang · +886 2 27891060 · karis.chiang@effpha.com
Always discuss trial participation with your own doctor first.
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung City, Taiwan | Not Yet Recruiting |
| Taichung Veterans General Hospital | Taichung, Taiwan | Recruiting |
| Koo Foundation Sun Yat-Sen Cancer Center | Taipei, Taiwan | Recruiting |
| Linkou Chang-Gung Memorial Hospital | Taoyuan City, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06012695